Abstracts tagged "Tumor necrosis factor (TNF)"

Abstract Number: 1012 • 2019 ACR/ARP Annual Meeting
Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis
Yannick Degboe ¹, Flavia Sunzini ¹, Iain McInnes ² and Carl Goodyear¹, ¹University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: PsA is associated with bone erosion and inflammation-induced bone loss. This process is mediated by osteoclasts, and modulated by inflammatory cytokines (i.e. TNF, IL-1,…
Abstract Number: 1446 • 2019 ACR/ARP Annual Meeting
Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
Klaus Krüger ¹, Gerd Burmester ², Siegfried Wassenberg ³, Astrid Thiele ⁴ and Matthias Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Charité—University Medicine Berlin, Berlin, Germany, ³Centre of Rheumatology, Ratingen, Germany, ⁴Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁵MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: The aim of this post hoc analysis is to assess effectiveness of GLM used as first, second, or at least third biologic agent in…
Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting
Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Santiago Rodrigues-Manica¹, Alexandre Sepriano ², Fernando Pimentel-Santos ¹, Nélia Gouveia ³, Anabela Barcelos ⁴, Jaime Branco ¹, Miguel Bernardes ⁵, Raquel Miriam-Ferreira ⁵, Elsa Vieira-Sousa ⁶, Sofia Barreira ⁶, Filipe Vinagre ⁷, Raquel Roque ⁷, Helena Santos ⁸, Nathalie Madeira ⁸, João Rovisco ⁹, Alexandra Daniel ⁹ and Sofia Ramiro ¹⁰, ¹CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ²Leiden University Medical Center, Leiden, Netherlands, ³CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, ⁴Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ⁵Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁶Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ⁷Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁸Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ⁹Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, ¹⁰Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands
Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…
Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting
Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study
Dongze WU¹, Priscilla Wong ¹, Steven H.M. Lam ¹, Isaac T. Cheng ¹, Edmund K. Li ¹, Ling Qin ¹ and Lai-Shan Tam ¹, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA). Nonetheless, whether these…
Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Alexis Ogdie¹, Ervant Maksabedian ², Bradley Stolshek ², Yomei Shaw ³ and Kaleb Michaud ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…
Abstract Number: 1871 • 2013 ACR/ARHP Annual Meeting
Progranulin Directly Binds To The CRD 2 and CRD3 Of TNFR Extracellular Domains
Jinlong Jian¹, Shuai Zhao¹, Qingyun Tian¹, Elena Gonzalez Gugel², Jyoti Mundra², Sardar MZ Uddin², Ben Liu³, Brendon Richbourgh², Ryan Brunetti², Gerald Chan⁴, Carolyn Green⁵ and Chuanju Liu¹, ¹Orthopaedic Surgery, NYU Hospital for Joint Diseases, New York, NY, ²NYU Hospital for Joint Diseases, New York, NY, ³NYU Hospital for Joint Diseases, New York Univerity, NY, ⁴Atreaon, Boston, MA, ⁵Atreaon, Boston, NY
Background/Purpose: We previously reported that Progranulin (PGRN) bound to TNF receptors (TNFR) and was therapeutic in inflammatory arthritis (Tang, W., et al, Science, 2011). PGRN…
Abstract Number: 471 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs
Bernard Combe¹, Bhaskar Dasgupta², Ingrid Louw³, Sarvajeet Pal⁴, Jürgen Wollenhaupt⁵, Cristiano Zerbini⁶, Andre D. Beaulieu⁷, Hendrik Schulze-Koops⁸, Patrick Durez⁹, Ruji Yao¹⁰, Nathan Vastesaeger¹¹ and Holly Weng¹⁰, ¹Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ²Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Advance Rheumatology Clinic, Hyderabad, India, ⁵Schön-Klinik, Hamburg, Germany, ⁶Centro Paulista de Investigações, Sao Paulo, Brazil, ⁷Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, ⁸University of Munich, Munich, Germany, ⁹UCL Saint-Luc, Brussels, Belgium, ¹⁰Merck Sharp & Dohme, Kenilworth, NJ, ¹¹Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: This study evaluated golimumab (GLM) as add-on therapy in patients with active RA despite treatment with non-biologic DMARDs. Two GLM treatment strategies (subcutaneous [SC]…
Abstract Number: 472 • 2012 ACR/ARHP Annual Meeting
More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes
Bhaskar Dasgupta¹, Bernard Combe², Ingrid Louw³, Sarvajeet Pal⁴, Jürgen Wollenhaupt⁵, Cristiano Zerbini⁶, Andre D. Beaulieu⁷, Hendrik Schulze-Koops⁸, Patrick Durez⁹, W. Bensen¹⁰, V. Wolff¹¹, Ruji Yao¹², Holly Weng¹² and Nathan Vastesaeger¹³, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Advance Rheumatology Clinic, Hyderabad, India, ⁵Schön-Klinik, Hamburg, Germany, ⁶Centro Paulista de Investigações, Sao Paulo, Brazil, ⁷Bureau 140, Centre de Rhumatologie, St. Louis, QC, Canada, ⁸University of Munich, Munich, Germany, ⁹UCL Saint-Luc, Brussels, Belgium, ¹⁰St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ¹¹Hospital del Salvador, Santiago, Chile, ¹²Merck Sharp & Dohme, Kenilworth, NJ, ¹³Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Little is known about how patient and physician expectations relate to clinical outcomes. This study investigated the expectations that patients and physicians have at…
Abstract Number: 1365 • 2012 ACR/ARHP Annual Meeting
Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I
Joachim Sieper¹, Jan Lenaerts², Jürgen Wollenhaupt³, Vadim Mazurov⁴, L. Myasoutova⁵, Sung-Hwan Park⁶, Yeong W. Song⁷, Ruji Yao⁸, Denesh Chitkara⁸ and Nathan Vastesaeger⁹, ¹Charité, University Medicine Berlin, Berlin, Germany, ²Reuma-instituut, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴St. Petersburg Medical Academy, St. Petersburg, Russia, ⁵Kazan State Medical University, Kazan, Russia, ⁶Catholic University of Korea, Seoul, South Korea, ⁷Seoul National University, Seoul, South Korea, ⁸Merck Sharp and Dohme, Kenilworth, NJ, ⁹Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Efficacy of anti–tumor necrosis factor (TNF) therapy in patients with axial spondyloarthritis (SpA) has been tested only in patients who are refractory to NSAIDs.…
Abstract Number: 834 • 2012 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Significantly Reduces Tumour-Necrosis-Factor-Alpha and Demonstrates Efficacy in Patients with Active Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, Randomised Trial
Anita Kåss¹, Øystein T. Førre², Morten Fagerland³, Hans Christian Gulseth⁴, Peter Torjesen⁵ and Ivana Hollan⁶, ¹University of Oslo, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Biostatistics, Oslo University Hospital, Oslo, Norway, ⁴Rheumatology, Betanien Hospital, Skien, Norway, ⁵Department of Endocrinology, Oslo University Hospital, Oslo, Norway, ⁶Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1) and therefore might…
Abstract Number: 779 • 2012 ACR/ARHP Annual Meeting
Changes in Active Inflammatory Lesions Assessed by Magnetic Resonance Imaging: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
Joachim Sieper¹, Jan Lenaerts², Jürgen Wollenhaupt³, Vadim Mazurov⁴, L. Myasoutova⁵, Sung-Hwan Park⁶, Yeong W. Song⁷, Ruji Yao⁸, Denesh Chitkara⁹ and Nathan Vastesaeger¹⁰, ¹Charité, University Medicine Berlin, Berlin, Germany, ²Reuma-instituut, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴St. Petersburg Medical Academy, St. Petersburg, Russia, ⁵Kazan State Medical University, Kazan, Russia, ⁶Catholic University of Korea, Seoul, South Korea, ⁷Seoul National University, Seoul, South Korea, ⁸Merck Sharp & Dohme, Kenilworth, NJ, ⁹Merck Sharp and Dohme, Kenilworth, NJ, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Few studies have evaluated changes in active inflammation of spine and sacroiliac (SI) joints by MRI during long-term treatment for axial SpA, and no…
Abstract Number: 549 • 2012 ACR/ARHP Annual Meeting
A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II
Joachim Sieper¹, Jan Lenaerts², Jürgen Wollenhaupt³, Vadim Mazurov⁴, L. Myasoutova⁵, Sung-Hwan Park⁶, Yeong W. Song⁷, Ruji Yao⁸, Denesh Chitkara⁹ and Nathan Vastesaeger¹⁰, ¹Charité, University Medicine Berlin, Berlin, Germany, ²Reuma-instituut, Hasselt, Belgium, ³Schön-Klinik, Hamburg, Germany, ⁴St. Petersburg Medical Academy, St. Petersburg, Russia, ⁵Kazan State Medical University, Kazan, Russia, ⁶Catholic University of Korea, Seoul, South Korea, ⁷Seoul National University, Seoul, South Korea, ⁸Merck Sharp & Dohme, Kenilworth, NJ, ⁹Merck Sharp and Dohme, Kenilworth, NJ, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: In patients with axial SpA who have achieved partial remission, it is unclear whether continuous treatment with NSAIDs is superior to stopping treatment. Objectives:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].